化合物简介
Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus and is sold as Torisel.
基本信息
中文名称
西罗莫司脂化物
英文名称
Temsirolimus
中文别名
替西罗莫司、西罗莫司
英文别名
CCL-779、Rapamycin (42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]、[14C]-Temsirolimus、TeMsiroliMus (CCI-779,Torisel)、TeMsiroliMus (~)、rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid、42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin、TeMsiroliMus (Torisel)、Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate、(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
CAS号
162635-04-3
分子式
C56H87NO16
分子量
1030.29
精确质量
1029.6
PSA
241.96
LOGP
5.6603
编号系统
UNII
624KN6GM2T
物化性质
密度
1.2g/cm3
沸点
1048.4ºC at 760mmHg
熔点
99-101ºC
闪点
587.8ºC
折射率
1.553
蒸汽压
0mmHg at 25°C
合成路线
